Fenwick & West represented MRL Ventures Fund, the strategic life sciences investment arm of Merck & Co., Inc. that is focused on innovative therapeutics companies developing transformative medicines, in a $59 million Series A financing for Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics. The financing was co-led by 5AM Ventures and MPM Capital, with MRL Ventures Fund, Roche Venture Fund and Agent Capital also participating.

More information regarding MRL Ventures’ participation in Entrada’s Series A financing can be obtained from the company announcement​.

The Fenwick transaction team was led by corporate partner Ian Goldstein, principal Eli Curi and associate Feihong Xu.

Login

Don’t have an account yet?

Register